haloperidol has been researched along with thallium in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Freedman, R; Hoffer, B; Marwaha, J | 1 |
| Amalric, M; Blobaum, AL; Bode, J; Bridges, TM; Bubser, M; Conn, PJ; Daniels, JS; Dickerson, JW; Engers, DW; Hopkins, CR; Italiano, K; Jadhav, S; Jones, CK; Lindsley, CW; Morrison, RD; Niswender, CM; Thompson, AD; Turle-Lorenzo, N | 1 |
2 other study(ies) available for haloperidol and thallium
| Article | Year |
|---|---|
Electrophysiological changes at a central noradrenergic synapse during thallium toxicosis.
Topics: Acetates; Amphetamine; Animals; Electric Stimulation; Electrophysiology; Haloperidol; Male; Norepinephrine; Purkinje Cells; Rats; Receptors, Adrenergic; Thallium | 1980 |
The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Brain; Calcium Signaling; Catalepsy; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Glutamic Acid; Haloperidol; HEK293 Cells; Humans; Levodopa; Male; Monoamine Oxidase; Motor Neuron Disease; Oxidopamine; Parkinson Disease; Picolinic Acids; Protein Binding; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reaction Time; Receptors, G-Protein-Coupled; Receptors, Metabotropic Glutamate; Substantia Nigra; Thallium; Transfection; Triazoles; Tyrosine 3-Monooxygenase | 2012 |